What would be the study design for gliclazide 80mg tablet for Europe, WHO & HKG [Regulatives / Guidelines]

posted by prasad.v – India, 2021-07-29 10:33 (56 d 23:43 ago) – Posting: # 22486
Views: 1,428

Dear All,

Little bit confusion raised as the Gliclazide is a NTI molecule, what would be the study design for gliclazide 80mg tablet BE study for Europe, WHO & HKG submission.
  1. Can we do the two-way crossover or full replicate fast and fed by widening AUC?
  2. Can we do the two-way crossover or full replicate fast and fed by widening AUC and Cmax?

Regards,
V. Prasad

Complete thread:

Activity
 Admin contact
21,693 posts in 4,535 threads, 1,541 registered users;
online 16 (2 registered, 14 guests [including 4 identified bots]).
Forum time: Friday 10:16 CEST (Europe/Vienna)

Tortured data will confess to anything.    Fredric Menger

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5